1.   It also significantly reduced the number of active lesions in the experimental group, compared to those in a control group.

2.   It also significantly reduced the number of active lesions in the patients who took the drug in tests against a control group.

3.   It also significantly reduced the number of active lesions in patients, compared to other patients in a control group.

4.   It also significantly reduced the number of active lesions in the patients compared to those in a control group.

5.   Those who are diagnosed with a late-onset progressive disease show abnormalities of the brain, but only a few active inflammatory lesions.